← SGLT2 inhibitors × glycemic control

SynthesisBMC endocrine disorders2025

Effects of canagliflozin on cardiovascular disease risk factors in patients with type 2 diabetes: a systematic review and meta-analysis.

Hossein Aftabi et al.PubMed ↗Full text ↗Publisher ↗

  • Canagliflozin at 100 mgno clear effectNo clear effect on systolic blood pressure, no clear effect on hemoglobin A1c, no clear effect on body mass index.Nothing cleared the noise.
  • Canagliflozin at 300 mgno clear effectNo clear effect on hemoglobin A1c, no clear effect on body mass index.Nothing cleared the noise.

What the trial testedas reported · 2025

Range includes no effect

No clear effect on systolic blood pressure

−0.03−0.07 to 0.00

canagliflozin at 100 mg vs placebo

As reported

difference −0.03, 95% CI −0.07 to 0.00

Range includes no effect

No clear effect on hemoglobin A1c

−0.01−0.04 to +0.03

canagliflozin at 100 mg vs placebo

As reported

difference −0.005, 95% CI −0.04 to 0.03

No range given

Reported higher glycemic control, no range given

+0.03

As reported

difference 0.03, no interval

Range includes no effect

No clear effect on hemoglobin A1c

−0.03−0.11 to +0.05

canagliflozin at 300 mg vs placebo

As reported

difference −0.03, 95% CI −0.11 to 0.05

+2 more in the walkthrough ↓

Who was studied, and how

people with hypertension, in this paper

The trial randomly assignedassigned by chance

canagliflozin at 100 mg
placebo

No clear effect on systolic blood pressure−0.03

No clear effect on hemoglobin A1c−0.01

No clear effect on body mass index−0.01

randomised

The trial randomly assignedassigned by chance

canagliflozin at 300 mg
placebo

No clear effect on hemoglobin A1c−0.03

No clear effect on body mass index+0.02

randomised

the abstract, start to end

… to that of placebo (effect size: -0.03 (-0.07, 0.00), (P = 0.06)].

… placebo [HbA1c at 100 mg, effect size: -0.005, Confidence Interval of 95% = -0.04 to 0.03, (P = 0.79), at 300 mg, effect size: -0.03 (-0.11 to 0.05), (P = 0.43), BMI at 100 mg, effect size: -0.01 (-0.04 to 0.02), (P = 0.57) and at 300 mg, …

← favours treatmentfavours comparator →
could be chance
No interval given · direction only, strength unknown
Systolic blood pressurecanagliflozin at 100 mg vs placebo
−0.03−0.07 to 0.00
Hemoglobin A1c (HbA1c)canagliflozin at 100 mg vs placebo
−0.005−0.04 to 0.03
Glycemic control
0.03
Hemoglobin A1c (HbA1c)canagliflozin at 300 mg vs placebo
−0.03−0.11 to 0.05
Body Mass Index (BMI)canagliflozin at 100 mg vs placebo
−0.01−0.04 to 0.02
Body Mass Index (BMI)canagliflozin at 300 mg vs placebo
0.02−0.05 to 0.10
SGLT2 inhibitorsGlycemic controlBody weight & compositionBlood pressure

SGLT2 inhibitors × glycemic controlhelps?replicated

unlikelylikely
0.92not counted

SGLT2 inhibitors × body weight & compositionhelps?settled

unlikelylikely
0.98not counted

SGLT2 inhibitors × blood pressurehelps?settled

unlikelylikely
0.88not counted
← favours treatmentfavours comparator →
more certainless certain
1 / 6

Not cited yet

Full record →Abstract, authors, funding and every citing paper · PMID 40604628